The aim of this observational study was to assess the prevalence of iron-restricted erythropoiesis (IRE) in a population of elderly hospitalized anemic patients. Prevalence of IRE was found to be 41% and the most common clinical diagnoses in such patients were hematologic malignancies and solid tumors. Comparison between patients with IRE and non-IRE patients revealed that mean corpuscular volume, mean corpuscular hemoglobin, iron, and transferrin saturation were significantly lower in the IRE group, whereas no significant difference was found for Hb, transferrin, or ferritin. There was a more pronounced inflammatory response in the IRE group demonstrated by a higher C-reactive protein level.
Introduction
Several different mechanisms can restrict erythropoiesis by supply of iron to the erythroblasts [1] . In absolute iron deficiency anemia, erythropoiesis is restricted by the depleted iron stores, whereas an inflammatory response induces iron-restricted erythropoiesis (IRE) by iron-sequestration [1] , commonly defined as ferritin >100 µg/L plus transferrin saturation (TSAT) ≤ 20% [2] or a bone marrow sample staining positive for iron in combination with TSAT ≤ 20%. The molecular mechanism by which an inflammatory response associated with autoimmune diseases, cancer, or infections induces blockage of intestinal iron absorption and efflux from reticuloendothelial system (RES) macrophages has been elucidated in recent years [3, 4] . An inflammatory response increases expression of the hepatic protein hepcidin in an interleukin-6-dependent manner [5] . Secreted hepcidin binds to the transmembrane iron transporter ferroportin in macrophages of the RES as well as in hepatocytes and enterocytes, down-regulating its expression by post-translational mechanisms [6] . In addition to decreased transport of iron from enterocytes to the circulation, the downregulated ferroportin reduces iron efflux from macrophages [7, 8] , thus making less iron available for erythropoiesis, the ultimate consequence of which is IRE and anemia [9] . Most of our current knowledge of IRE and its treatment with iron supplementation stems from the nephrology setting [10] . In nephrology, IRE is commonly known as functional iron deficiency (FID) and seen in patients with chronic kidney disease (CKD) who are treated with erythropoiesis stimulating agents (ESAs). In these patients, an ESA-driven supraphysiological erythropoiesis is restricted by the delivery of stored iron to the bone marrow erythroblasts, which can lead to ESA-hyporesponsiveness. This condition can be successfully treated by intravenous (iv) iron supplementation [10] . FID is also seen in cancer patients on ESA therapy, and the addition of iv iron has been found to augment the erythropoietic response in this patient group [11] .
Material and Methods
This study was conducted at the Department of Medicine, Capio Sankt Görans Hospital, Stockholm, Sweden. One hundred and four newly diagnosed anemic patients (Hb < 134 g/L in men and <117 g/L in women) 60 years of age or older admitted to the hospital were screened for IRE, defined as a bone marrow smear staining positive for iron in combination with TSAT ≤ 20%. This observational study was performed on blood and bone marrow samples collected during routine anemia investigation and all procedures were in accordance with the Helsinki Declaration of 1964. Patients receiving iron supplementation or red cell transfusions were excluded from the study. Bone marrow smears were stained by means of the May-Grunwald-Giemsa method, and bone marrow iron stores were investigated using Prussian blue staining. Patients with no stainable bone marrow iron (n = 38) were diagnosed as having absolute iron deficiency. The diagnosis for Copyright © 2012 SciRes.
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those with stainable iron was anemia of chronic disease (ACD) or other non-iron deficiency anemia. The iron replete patients were divided into two groups: those with IRE (n = 43) and those with non-IRE anemia (bone marrow staining positive for iron + TSAT > 20%) (n = 23). Hematological data, biochemical iron status and C-reactive protein (CRP) were compared between the IRE and non-IRE groups. Complete blood counts were performed using the ADVIA 2120 analyzer (Siemens Diagnostics, Deerfield, IL, USA). CRP, iron, and transferrin were investigated by means of ADVIA 2400 and sTfR using BN ProSpec (Siemens Diagnostics, Deerfield, IL, USA). Ferritin was analyzed using ADVIA Centaur XP. All reagents were from Siemens Diagnostics, with the exception of the transferrin assay, which was produced by Dakopatts (Dakopatts, Dorchester, UK 
Results and Discussion
The aim of this observational study was to assess the prevalence of IRE in a population (n = 104) of elderly hospitalized anemic patients and to compare hematological and biochemical iron data between the IRE and non-IRE groups. The prevalence of IRE in this population was 41% (43/104). The mean age in the IRE group was 83 years versus 78 in the non-IRE group. This age difference was not statistically significant. The main clinical diagnoses among the anemic patients with IRE were hematologic malignancies (26%), solid tumors (18%), and infections (17%) ( Table 1) , while in the non-IRE group, infections (22%), CKD (22%) and liver disease (17%) were the most common ( Table 1) . Interestingly, 44% (20/43) of the patients in the IRE group suffered from hematologic malignancies or solid tumors compared to 13% (3/23) in the non-IRE group. The explanation behind this difference is unclear, but it is possible that malignant cells induce a cytokine "profile" in the organism that differs from that induced by an inflammatory response associated with non-malignant disease and that these different "profiles" have divergent effects on the iron metabolism [12] . Iron, TSAT, MCV, and MCH were all significantly lower in the IRE group compared to the non-IRE group ( Table 2) . The significantly lower iron, TSAT, MCV, and MCH values in the IRE group compared to the non-IRE group indicate a higher degree of iron blockage in the first group ( Table  2) . No significant differences in Hb, transferrin or ferritin were detected when comparing the two groups ( Table 2) . The lower TSAT in the IRE group was solely an effect of a lower iron concentration ( Table 2) . Transferrin is commonly regarded as a "negative" acute-phase reactant [13] , but in the population described here, there was no difference between mean transferrin concentrations when comparing the IRE and non-IRE groups, despite a more pronounced inflammatory response in the IRE group determined by a higher mean concentration of CRP (Table 2). The mean concentration of sTfR was significantly higher in the IRE group compared to the non-IRE group ( Table 2) . The most obvious explanation for this finding is that due to the higher degree of iron blockage in the IRE group, a subsequent lower serum iron concentration stimulates bone marrow erythroblasts to increase their expression of TfR. In previous studies on sTfR levels in ACD, subjects with IRE and non-IRE were not analyzed separately [14, 15] . The significantly lower MCH in the IRE group compared to the non-IRE group probably reflects a higher degree of iron restriction in the former. Since MCH reflects mean red cell hemoglobinization over the life of the red cell, i.e. 120 days, the lower MCH in the IRE group indicate that the iron restriction is not a phenomenon with an acute onset. Anemia of chronic disease is a common phenomenon associated with conditions such as autoimmune diseases, cancer, and infections [16] , and the pathogenetic mechanisms behind IRE partly overlap those in ACD [1, 17] . There are limited data on IRE in populations of elderly patients with co-morbid conditions. In a population of anemic oncology patients with a mean age of over 60 years, the prevalence of IRE, determined by ferritin >100 µg/mL and TSAT < 20% was 46% prior to initiation of therapy [18] . One trial reported an IRE prevalence of 27% in a population of elderly patients undergoing orthopaedic surgery [19] . An IRE prevalence of 35% was observed in a population of intensive care patients (n = 51) [20] that did not only include elderly patients (median age approx. 60). Furthermore, analysis of the percentage of hypochromic erythrocytes has been used to identify subjects (median age 71 years, range 18 -84 years) with IRE and hyporesponsiveness to ESA in a population of patients with lymphoproliferative malignancies [21] . In the nephrology setting, Mirescu and co-workers [22] demonstrated that in a population of anemic CKD patients (mean age 52 years) without absolute iron deficiency, treatment with iv iron increased Hb in parallel with an increase in the percentage of patients with TSAT > 20% from 59 (baseline) to 97% at the end of the study period. The FAIR-HF trial revealed that intravenous iron significantly improved symptoms and functional capacity in a population of iron deficient patients (mean age approx. 67 years) with congestive heart failure [23] . Subjects in the FAIR-HF trial were considered iron deficient if serum ferritin was (a) less than 100 µg/L or (b) between 100 and 299 µg/L in combination with a transferrin saturation less than 20%. The criterion in (b) suggests that at least a subgroup of patients suffered from IRE but were not reported separately [23] . Intravenous iron therapy has also been found to significantly increase Hb in anemic patients with rheumatoid arthritis [24] .
Conclusion
The results presented here indicate a 41% prevalence of IRE in a population of elderly hospitalized anemic patients and that the most common clinical diagnoses associated with IRE are hematologic malignancies and solid tumors. Iron restriction was of the sequestration type, since all patients were iron replete and serum iron was significantly lower in the IRE group. Furthermore, there was a more pronounced inflammatory response in the IRE group determined by the higher level of CRP. These findings and the results of iv iron therapy in IRE outside the hematology/oncology setting highlight the need for clinical trials with iv iron in cancer patients with IRE.
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